215P Proteogenomics to guide neoantigen discovery in non-small cell lung cancer

Abstract

Targeted Immunotherapy is entirely dependent on the identification of suitable TAAs or even better, of TSAs, also referred to as neoantigens. This is currently an extremely challenging task, mainly based on using experimental data from DNA and RNA sequencing technologies to generate large lists of neoantigen candidates, followed by heavy bioinformatics to predict how well each neoantigen candidate would progress through the MHC processing and presentation pathway. Up till now, most of the candidates generated in this way fail to elicit any relevant immunogenicity.